Clinical Trial Update: Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB [Phase 3]

View source ↗

Summary

Phase 3 efficacy study comparing a single-dose levalbuterol tartrate HFA MDI to placebo in adults with exercise-induced bronchospasm has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exercise-induced Bronchospasm

Drugs mentioned

• Levalbuterol Tartrate HFA MDI (Levalbuterol tartrate)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Exercise-induced Bronchospasm | Phase 3 | Status: COMPLETED